Biotech Values

[mskatiescarletohara]

Another heavyweight joins GENR. I like the way this company has been able to attract solid executive management with impressive resumes in the past few months. I suspect Mr. Imasogie will be an important asset to the BOD regarding negotiations with potential partners or acquisitions. Only 20K in options, I am a little surprised at the low number, I expected more given his experience.

I agree about NO GSK collaboration, that would be a conflict of interest. Scratch them off the list of potential collaborators.

katie...